# Sir Run Run Shaw Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/sir-run-run-shaw-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 29.1 |
| Citations | 1,359,495 |
| City | Hangzhou |
| Country | CN |
| Description | Sir Run Run Shaw Hospital is a research organisation in Hangzhou, CN. OpenAlex records 18,316 works and 1,359,495 citations for it. 7,001 researchers list it as their most recent affiliation. |
| Homepage | http://www.srrsh.com/html/main/gb2312/ |
| OpenAlex ID | https://openalex.org/I2802390878 |
| Researchers | 7,001 |
| ROR ID | https://ror.org/00ka6rp58 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q7528920 |
| Works | 18,316 |

## University papers

Showing 12 of 91.

- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial](https://scholariq.org/papers/linifanib-versus-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)
- [Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial](https://scholariq.org/papers/intercalated-combination-of-chemotherapy-and-erlotinib-for-patients-with/)
- [A global perspective on the convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae](https://scholariq.org/papers/a-global-perspective-on-the-convergence-of-hypervirulence-and-carbapenem/)
- [YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis](https://scholariq.org/papers/yap-regulates-actin-dynamics-through-arhgap29-and-promotes-metastasis/)
- [Completeness Modeling and Context Separation for Weakly Supervised Temporal Action Localization](https://scholariq.org/papers/completeness-modeling-and-context-separation-for-weakly-supervised-temporal/)
- [Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial](https://scholariq.org/papers/tepotinib-plus-gefitinib-in-patients-with-egfr-mutant-non-small-cell-lung-cancer/)
- [Relationship between exposure to PM2.5 and lung cancer incidence and mortality: A meta-analysis](https://scholariq.org/papers/relationship-between-exposure-to-pm2-5-and-lung-cancer-incidence-and-mortality-a/)
- [SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD](https://scholariq.org/papers/scfas-alleviated-steatosis-and-inflammation-in-mice-with-nash-induced-by-mcd/)

## University researchers

- [Tingting Jiang](https://scholariq.org/researchers/tingting-jiang/)
- [Jiancang Zhou](https://scholariq.org/researchers/jiancang-zhou/)
- [Chang Liu](https://scholariq.org/researchers/chang-liu/)
- [Engeng Chen](https://scholariq.org/researchers/engeng-chen/)
- [Qiqi He](https://scholariq.org/researchers/qiqi-he/)
- [Kong-Han Pan](https://scholariq.org/researchers/kong-han-pan/)
- [Haiou Qi](https://scholariq.org/researchers/haiou-qi/)
- [Peiqi Liu](https://scholariq.org/researchers/peiqi-liu/)

## University top topics

Showing 8 of 25.

- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [MicroRNA in disease regulation](https://scholariq.org/topics/microrna-in-disease-regulation/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.